Reneo Pharmaceuticals Inc expected to post a loss of 57 cents a share - Earnings Preview

Onkure Therapeutics

03/11/2023 16:21

* Reneo Pharmaceuticals Inc  RPHM.OQ   RPHM.O  is expected
to show
no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Reneo
Pharmaceuticals Inc
is for a loss of 57 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Reneo
Pharmaceuticals Inc is $25​, above​ its last closing price
of $7.95. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.50       -0.52      -0.65     Missed  -25.8
 Mar. 31 2023  -0.59       -0.60      -0.60     Met     0.7
 Dec. 31 2022              -0.60      -0.56     Beat    6.8​
 Sep. 30 2022  -0.57       -0.57      -0.53     Beat    7.3
 ​​Jun.        -0.58       -0.58      -0.50     Beat    14.1
 30 2022                                                
 Mar. 31 2022  -0.52       -0.54      -0.53     Beat    2.5​
 Dec. 31 2021  -0.56       -0.57      -0.43     Beat    24.6
 Sep. 30 2021  -0.48       -0.47      -0.52     Missed  -9.9
 This summary was machine generated November 3 at 16:21 GMT.  All
figures in US dollars  unless otherwise stated